We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
13
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
EMA
European Medicines Agency
3
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
10
• NICE has terminated its appraisal of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer in patients unsuitable for platinum-doublet chemotherapy. • Roche Products declined to submit evidence for the appraisal, citing concerns that there would be insufficient data to demonstrate cost-effectiveness in the NHS setting. • The decision affects adult patients with advanced NSCLC who cannot receive standard platinum-based chemotherapy, limiting their treatment options in the UK healthcare system.
